[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539158":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":27,"centralContacts":32,"locations":37,"responsibleParty":54,"collaborators":24,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":24,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":24,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Beijing Tongren Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Interleukin-4 receptor responders","EXPERIMENTAL","Interleukin-4 receptor was injected subcutaneously.",[13],"Biological: Interleukin-4 receptor responders",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo was injected subcutaneously.",[19],"Other: Placebo",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL",[9],null,{"type":6,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"affiliation":30,"role":31},"Luo Zhang","Beijing Tong-Ren hospital","STUDY_CHAIR",[33],{"name":29,"role":34,"phone":35,"phoneExt":24,"email":36},"CONTACT","+86-13910830399","dr.luozhang@139.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Beijing Tongren Hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100000","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53],{"name":29,"role":34,"phone":35,"phoneExt":24,"email":36},{"type":55,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100539158","phase-2-study-of-cm310-in-patients-with-uncontrolled-seasonal-allergic-rhinitis-100539158",false,"NCT06300203","Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis","The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit (IL-4Rα) in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment： A Randomized, Double-Blind, Placebo-controlled IIT Study","MEGREZ","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Have any condition that are not suitable for participating in this study.","ALL","18 Years","65 Years",{"count":68,"type":69},120,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.",[75],"Seasonal Allergic Rhinitis","2025-09-20",{"date":78,"type":79},"2025-09-25","ACTUAL",{"date":81,"type":79},"2024-03-18",{"date":83,"type":69},"2026-06-30",{"name":5,"class":6},1]